Clone:
REAL1004
Type of antibody:
Releasable fluorochromes, Primary antibodies, Recombinant antibodies
Applications:
MICS, IHC, IF
Alternative names:
VEGF-A, Vascular Endothelial Growth Factor

Specifications for VEGF Antibody, anti-human, REAdye_lease™

Overview

Clone REAL1004 is an antibody fragment derived from the full VEGF antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL1004 recognizes the VEGF protein, also known as VEGFA (Vascilar Endothelial Growth Factor), a member of the PDGF/VEGF growth factor family and is essential for both physiological and pathological angiogenesis. Alternatively spliced transcript variants encoding different isoforms have been described. The gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Allelic variants of the gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675).

Alternative names

VEGF-A, Vascular Endothelial Growth Factor

Detailed product information

Technical specifications

CloneREAL1004
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable fluorochromes, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenVEGF
Alternative names of antigenVEGF-A, Vascular Endothelial Growth Factor
Distribution of antigenlung

References for VEGF Antibody, anti-human, REAdye_lease™

Publications

  1. Terme, M. et al. (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73(2): 539-549
  2. Claesson-Welsh, L. et al. (2013) VEGFA and tumour angiogenesis. J Intern Med 273(2): 114-127

Seems like you are coming from USA!
Do you want to visit our website in your country?